EMvision Research Notes, page-2610

"I would be delighted if the Company could go commercial with emu in late 2025"

No doubt that would be a fantastic outcome for all shareholders. I would say "I would be delighted if the company could go commercial".

Whether it's late 2025 or mid to late 2026 doesn't concern me. The most important question that we await is "will the validation trial be successful?" because if that is successful the rest will follow ie. FDA and commercialisation. Two years from now is a realistic prediction. Two years may seem like a lifetime for most small cap punters/investors but in the big picture it's nothing. I believe we will see a substantial re-rate BEFORE commercialisation if the validation trial is successful. We can only judge a company's future prospects on the past performance and to date EMV management has displayed impeccable business acumen including exemplary capital management which has led the company to the cusp of commercialisation and still sub 100M shares on issue. I agree with stotes.

This is not just about brain scanning for stroke. EMV has patented a technology that will likely be the fourth imaging modality on the planet after Ultrasound, CT and MRI. A new frontier in medical imaging. Exciting times ahead and potentially the beginning of a multi billion dollar company.